Tech Firms Face Growing Resentment Toward Parent Employees During COVID-19
This week Moderna “said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, reports Reuters, “offering the clearest timeline yet for when the world will know whether it is effective.”

The company, one of the front-runners in the global race to produce vaccines to protect against COVID-19, said an independent data monitoring committee is expected to conduct an interim review of its ongoing 30,000-person trial in November… The company said it is preparing to distribute the vaccine, known as mRNA-1273, and expects to be able to produce 20 million doses by the end of the year, and between 500 million and 1 billion in 2021. Moderna said infection rates in the trial were on track with expectations…
Moderna said it expects two-month follow-up safety data, as required by the U.S. Food and Drug Administration, in the second half of November, after which it will file for an emergency use authorization.

Read more of this story at Slashdot.

By admin